Pridopidine

Pridopidine is a pharmaceutical compound that has been investigated for its potential therapeutic effects in neurodegenerative disorders, particularly Huntington's disease. It is classified as a dopamine receptor stabilizer, which means it modulates the activity of dopamine receptors in the brain.
Mechanism of Action[edit]
Pridopidine primarily acts as a sigma-1 receptor agonist. The sigma-1 receptor is a chaperone protein located in the endoplasmic reticulum of cells and is involved in modulating calcium signaling, neuroprotection, and neuroplasticity. By activating the sigma-1 receptor, pridopidine is thought to exert neuroprotective effects, which may be beneficial in conditions like Huntington's disease.
Clinical Applications[edit]
Huntington's Disease[edit]
Pridopidine has been studied in clinical trials for its potential to alleviate symptoms of Huntington's disease, a genetic disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric symptoms. The drug's ability to stabilize dopamine receptor activity and its action on the sigma-1 receptor are believed to contribute to its therapeutic effects.
Other Potential Uses[edit]
While the primary focus of pridopidine research has been on Huntington's disease, there is interest in exploring its effects in other neurodegenerative disorders, such as Parkinson's disease and amyotrophic lateral sclerosis (ALS), due to its neuroprotective properties.
Pharmacokinetics[edit]
Pridopidine is administered orally and is absorbed into the bloodstream, where it crosses the blood-brain barrier to exert its effects on the central nervous system. The drug is metabolized in the liver and excreted primarily through the kidneys.
Safety and Tolerability[edit]
In clinical trials, pridopidine has been generally well-tolerated, with a safety profile similar to that of other drugs targeting the central nervous system. Common side effects include mild gastrointestinal disturbances and dizziness.
Research and Development[edit]
Ongoing research is focused on understanding the full range of pridopidine's effects on the brain and its potential applications in various neurological conditions. Studies are also investigating optimal dosing regimens and long-term safety.
Related Pages[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian